Business Wire·Aug 20, 2026, 8:00 AM ET

Turn Therapeutics Announces New Peer-Reviewed Research Showing GX-03 Selectively Reduces Key Drivers of Skin Inflammation and Itch

Turn Therapeutics announced peer-reviewed in-vivo research published in Life showing its investigational therapy GX-03 reduces key inflammatory signals in a murine dermatitis model.
Pretreatment with GX-03 reduced IL-36 (a key early driver of inflammation) by approximately 50% and IL-31 (a major driver of itch) by nearly 68%.
The study observed a 16.7% reduction in IL-4 levels, while IL-13 levels remained essentially unchanged, indicating a selective pattern of cytokine reduction.
Animals treated with GX-03 prior to Staphylococcus aureus exposure showed a 66% reduction in clinical dermatitis severity compared to untreated controls.
The intervention timing is significant as GX-03 modified the local skin environment upstream before the inflammatory cascade was fully established, differing from therapies that target established inflammation.
No local irritation, dryness, redness, or barrier disruption was observed during the four-day GX-03 pretreatment period in the study of 36 mice.
GX-03 is a proprietary, non-systemic topical therapy currently under evaluation in a randomized, double-blind, vehicle-controlled clinical trial for atopic dermatitis.